Exploring the effect of antenatal depression treatment on children's epigenetic profiles:findings from a pilot randomized controlled trial by Bleker, Laura S. et al.
  
 University of Groningen
Exploring the effect of antenatal depression treatment on children's epigenetic profiles
Bleker, Laura S.; Milgrom, Jeannette; Sexton-Oates, Alexandra; Roseboom, Tessa J.;






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Bleker, L. S., Milgrom, J., Sexton-Oates, A., Roseboom, T. J., Gemmill, A. W., Holt, C. J., ... de Rooij, S. R.
(2019). Exploring the effect of antenatal depression treatment on children's epigenetic profiles: findings
from a pilot randomized controlled trial. Clinical Epigenetics, 11, [18]. https://doi.org/10.1186/s13148-019-
0616-2
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
SHORT REPORT Open Access
Exploring the effect of antenatal depression
treatment on children’s epigenetic profiles:
findings from a pilot randomized controlled
trial
Laura S. Bleker1,2* , Jeannette Milgrom3,4, Alexandra Sexton-Oates5, Tessa J. Roseboom1,2, Alan W. Gemmill3,
Christopher J. Holt3, Richard Saffery5, Huibert Burger6 and Susanne R. de Rooij2
Abstract
Background: Children prenatally exposed to maternal depression more often show behavioral and emotional
problems compared to unexposed children, possibly through epigenetic alterations. Current evidence is largely based
on animal and observational human studies. Therefore, evidence from experimental human studies is needed. In this
follow-up of a small randomized controlled trial (RCT), DNA-methylation was compared between children of women
who had received cognitive behavioral therapy (CBT) for antenatal depression and children of women who had
received treatment as usual (TAU). Originally, 54 women were allocated to CBT or TAU. A beneficial treatment effect
was found on women’s mood symptoms.
Findings: We describe DNA methylation findings in buccal swab DNA of the 3–7-year-old children (CBT(N) = 12, TAU(N) = 11)
, at a genome-wide level at 770,668 CpG sites and at 729 CpG sites spanning 16 a priori selected candidate
genes, including the glucocorticoid receptor (NR3C1). We additionally explored associations with women’s baseline
depression and anxiety symptoms and offspring DNA methylation, regardless of treatment. Children from the CBT
group had overall lower DNA methylation compared to children from the TAU group (mean Δβ = − 0.028, 95% CI − 0.
035 to − 0.022). Although 68% of the promoter-associated NR3C1 probes were less methylated in the CBT group, with
cg26464411 as top most differentially methylated CpG site (p = 0.038), mean DNA methylation of all NR3C1 promoter-
associated probes did not differ significantly between the CBT and TAU groups (mean Δβ = 0.002, 95%CI − 0.010 to 0.
011). None of the effects survived correction for multiple testing. There were no differences in mean DNA methylation
between the children born to women with more severe depression or anxiety compared to children born to women
with mild symptoms of depression or anxiety at baseline (mean Δβ (depression) = 0.0008, 95% CI − 0.007 to 0.008;
mean Δβ (anxiety) = 0.0002, 95% CI − 0.004 to 0.005).
Conclusion: We found preliminary evidence of a possible effect of CBT during pregnancy on widespread methylation
in children’s genomes and a trend toward lower methylation of a CpG site previously shown by others to be linked to
depression and child maltreatment. However, none of the effects survived correction for multiple testing and larger
studies are warranted.
Trial registration: Trial registration of the original RCT: ACTRN12607000397415. Registered on 2 August 2007.
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Background
Many pregnant women experience clinically significant de-
pressive symptoms before delivery, with an estimated preva-
lence of 7.4 to 12.8% [1]. Mounting evidence demonstrates
that children prenatally exposed to maternal depression
more often have a difficult temperament [2], are more prone
to develop internalizing and externalizing behavioral prob-
lems [3–7], show poorer performance on cognitive tasks [8,
9], and more often develop depression and anxiety symp-
toms themselves in (pre)adolescence [10–12]. One mechan-
ism by which antenatal depression might influence
susceptibility for psychopathology is by epigenetic regulation
of gene expression [13, 14]. Epigenetic mechanisms regulate
the activity of DNA and include post-translational histone
modification, micro-RNAs, and DNA methylation [15]. In
contrast to the fixed genotype, the epigenome has shown to
be highly variable early in development under the influence
of environmental factors [16, 17].
Animal studies have provided evidence that antenatal
stress alters methylation of offspring genes involved in neu-
rodevelopment and is associated with behavioral changes.
For example, exposure to chronic stress in early gestation in
mice resulted in a stress-sensitive phenotype in male off-
spring, showing increased immobility in the tail suspension
and forced swim test and heightened hypothalamic pituitary
adrenal (HPA) axis responsivity, which was accompanied by
increased DNA methylation and decreased gene expression
of the glucocorticoid receptor in the hippocampus and
amygdala [18]. Moreover, alterations in epigenetic profiles
have been shown to remain stable across generations, pass-
ing on susceptibility for emotional and behavioral disorders
from one generation to the next [19].
Since 2008, many human studies have investigated asso-
ciations between prenatal stress exposure and offspring
gene methylation, with a special focus on NR3C1, coding
for the glucocorticoid receptor [20]. While the reported
effect sizes are usually small, increased methylation status
of NR3C1 has been linked to an increased HPA axis
stress-response [21]. All studies to date are, however, ob-
servational and therefore susceptible to confounding by
factors that are both associated with antenatal stress and
with methylation patterns, such as maternal smoking
during pregnancy [22]. Experimental designs including
follow-up of children are currently scarce and ur-
gently needed to establish causality between intrauter-
ine exposures and later life outcomes [23].
The current study investigated effects of maternal
depression treatment during pregnancy on DNA
methylation profiles in the children. In the Beating
the Blues before Birth (BBB) study, pregnant women
with a confirmed Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition (DSM-IV) depressive
disorder were randomized to either the intervention
group, consisting of eight cognitive behavioral therapy
(CBT) sessions, or to a control group, consisting of treat-
ment as usual (TAU), which comprised case-managing by
a midwife or referral to a general practitioner. Beneficial
treatment effects favoring the intervention were found on
maternal depression and anxiety. Anxiety symptoms sig-
nificantly decreased, and depressive symptoms showed a
decreasing trend nearly reaching significance, in the inter-
vention versus the control group [24].
We hypothesized that compared to the control group, the
intervention would be associated with a change in DNA
methylation profiles of buccal swab DNA from the children,
(1) at an epigenome-wide level, (2) at 16 a priori selected
candidate genes, and (3) at promoter-associated glucocortic-
oid receptor (NR3C1) probes. We additionally explored
whether severity of maternal symptoms of depression and
anxiety at baseline would be associated with DNA methyla-
tion profiles in the children, regardless of treatment.
Results
Study sample characteristics
Of the original study group of 54 women, 2 women had
moved overseas to unknown addresses, and 10 women
could not be traced. This resulted in 42 women being invited
to participate in the current study. In total, 19 women de-
clined to participate. Reasons for declining were lack of time,
a lack of interest in being involved, or not wanting their
child’s DNA to be used for study purposes. This resulted in
a study group of 23 women and their children who agreed
to participate in the current study, 12 (42.9%) women from
the intervention group and 11 (42.3%) women from the con-
trol group (flowchart; Fig. 1). Table 1 shows baseline charac-
teristics of all women from the original study, women that
did not participate, and women that did participate in the
current follow-up. In the intervention and control group
alike, women that responded to the current follow-up had
lower Beck Depression Inventory (BDI-II) and lower Beck
Anxiety Inventory (BAI) scores, less often reported using an-
tidepressants, and were more highly educated with a higher
annual income compared to non-responders at baseline. In
the intervention group, participating women were more
often born in Australia and married compared to women
who did not participate, whereas in the control group,
women were less often born in Australia and married com-
pared to non-responders. Current demographics of the
women and their children are shown in Table 2. Less
women from the intervention group were currently using an
antidepressant, their income was higher, and they more
often drank one or more alcoholic unit per week, as com-
pared to the control group.
Association between genome-wide DNA methylation and
allocation
Linear regression analysis was used to identify specific
differentially methylated probes according to allocation.
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This took into account variation associated with the
following covariates: birth weight, HM850 array chip
position, sex and age, as identified by principal compo-
nent analysis (PCA). Linear regression analysis revealed
a total of 4780 differentially methylated probes at a
nominal significance level (p < 0.01, uncorrected for
multiple testing) between the intervention and the con-
trol group, showing higher DNA methylation in the
control group (mean Δβ = − 0.028, 95% CI − 0.035 to −
0.022, p < 0.001). Adding current income as an additional
covariate did not significantly alter the results (mean Δβ =
− 0.026, 95% CI − 0.031 to − 0.021, p < 0.001). The top 100
differentially methylated probes are presented in Table 3
of the Appendix. Table 4 shows the ten most differentially
methylated probes. Of the top five differentially meth-
ylated probes, three probes with annotated genes were probe
cg15495292 on the AIG1 gene (uncorrected p= 4.01E-06,
corrected p = 0.999), cg05155812 on the SUN1 gene
(uncorrected p = 1.56E-05, corrected p = 0.999), and
cg18818484 on the PTCHD2 gene (uncorrected p=2.20E-05, cor-
rected p = 0.999). After correcting for multiple testing
(corrected p ≤ 0.01), no probes remained significantly
associated with the intervention.
Candidate gene-specific DNA methylation and allocation
In addition to an exploratory genome-wide analysis
(above), we also tested for associations with a list of a
priori chosen candidate genes. Table 5 shows the results
of the unpaired Mann-Whitney-Wilcoxon tests, compar-
ing mean DNA methylation of 16 candidate genes be-
tween the intervention and control group. No genes
were significantly differentially methylated at a nominal
Fig. 1 Flow diagram of participant recruitment. *Comorbid axis I disorders, medical conditions at risk for interference with study participation, concurrent
major psychiatric disorders for which the intervention was not designed (e.g., bipolar and psychotic disorder), risk requiring crisis management, current
participation in other psychological programs, or significant difficulty with English. CBT cognitive behavioral therapy, TAU treatment as usual
Bleker et al. Clinical Epigenetics           (2019) 11:18 Page 3 of 24
significance level p < 0.01. Trends toward lower DNA
methylation in the CBT group compared to the TAU
group were seen in the OXTR, MEST, MEG3, H19, and
CRHR2 genes. Table 6 of the Appendix shows the probes
of the candidate genes that were differentially methyl-
ated at a nominal significance level p < 0.01.
The glucocorticoid receptor (NR3C1) gene and allocation
Mean DNA methylation of 34 promoter-associated NR3C1
probes (Table 7 in Appendix) did not differ significantly be-
tween the intervention and control group (mean Δβ= 0.002,
95% CI − 0.010 to 0.011). One probe, cg26464411, showed a
trend toward lower methylation in the intervention group
(Table 7 in Appendix, Fig. 2).
Association between genome-wide DNA methylation and
baseline depression/anxiety
Depression
Linear regression analysis (adjusted for birth weight, HM850
array chip position, sex, age, and allocation) revealed a total
of 3065 differentially methylated probes at a nominal signifi-
cance level (p < 0.01) between the groups of children from
the antenatally severely depressed women versus the group
of children from the antenatally mildly depressed women.
Mean DNA methylation values were not significantly differ-
ent between children born to the severely depressed and the
mildly depressed women (mean Δβ= 0.0008 95% CI − 0.007
to 0.008, p= 0.95). The top 100 differentially methylated
probes according to depression severity at baseline are
Table 1 Baseline characteristics of all participants in a trial evaluating an antenatal cognitive behavioral therapy (CBT) versus
treatment as usual (TAU), those that responded, and those that did not respond to the 5-year follow-up




Baseline demographics CBT (n = 28) TAU (n = 26) CBT (n = 16) TAU (n = 15) CBT (n = 12) TAU (n = 11)
Mean (SD) BDI pre-treatment score 30.8 (9.5) 30.5 (8.9) 31.6 (9.7) 31.2 (7.8) 29.6 (9.5) 29.5 (10.4)
Mean (SD) BAI pre-treatment score 22.8 (10.0) 21.2 (10.2) 25.4 (10.1) 22.8 (12.2) 19.2 (9.0) 19.3 (7.1)
Mean (SD) BDI post-treatment score 13.0 (9.8) 17.4 (9.8) 12.9 (10.1) 17.3 (10.8) 13.0 (10.0) 17.6 (9.0)
Mean (SD) BAI post-treatment score 10.6 (7.6) 16.7 (11.8) 9.6 (5.4) 17.6 (14.3) 11.6 (9.9) 15.3 (7.1)
Mean (SD) Δ BDI score (post-treatment − pre-treatment) − 18.6 (10.0) − 13.2 (12.8) − 20.4 (12.0) − 14.5 (10.4) − 16.6 (7.3) − 11.5 (16.1)
Mean (SD) Δ BAI score (post-treatment − pre-treatment) − 11.2 (9.4) − 4.3 (8.3) − 14.5 (10.1) − 5.0 (9.8) − 7.5 (7.2) − 3.1 (6.0)
Mean (SD) maternal age in years 32.9 (5.9) 31.0 (5.8) 32.2 (6.5) 29.2 (5.6) 33.7 (5.7) 33.6 (5.2)
Mean (SD) gestational age in weeks 19.9 (7.7) 21.0 (6.0) 21.2 (8.0) 22.6 (6.1) 18.3 (7.2) 19.0 (5.5)
Antidepressant use (%) 7.1 22.7 14.3 26.7 – 11.1
Marital status (%)
- Married 57.7 65.2 46.7 69.2 72.7 60.0
- De Facto 34.6 21.7 46.7 15.4 18.2 30.0
- Separated – 8.7 – 7.7 – 10.0
- Single 7.7 4.3 6.7 7.7 9.1 –
Birth location (%)
- Australia 73.1 82.6 66.7 84.6 81.8 80.0
- Other 26.9 17.4 33.3 15.4 18.2 20.0
Income (%)
- Up to $ 20,000 – 4.5 – – – 10.0
- $ 20,001–$ 40,000 8.0 22.7 7.1 25.0 9.1 20.0
- $ 40,001–$ 60,000 20.0 13.6 28.6 16.7 9.1 10.0
- $ 60,001–$ 80,000 28.0 27.3 21.4 33.3 36.4 20.0
- > $ 80,001 32.0 31.8 28.6 25.0 36.4 40.0
- Do not wish to divulge 12.0 - 14.3 - 9.1 –
Highest level of education (%)
- Did not finish school 3.8 12.0 6.7 21.4 – –
- High School 7.7 24.0 13.3 21.4 – 27.3
- Certificate Level/Apprenticeship 23.1 4.0 33.3 – 9.1 9.1
- Advanced Diploma 19.2 4.0 6.7 7.1 36.4 –
- Bachelor degree 11.5 24.0 20.0 28.6 – 18.2
- Graduate diploma/certificate 19.2 16.0 6.7 7.1 36.4 27.3
- Postgraduate Degree 15.4 16.0 13.3 14.3 18.2 18.2
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presented in Table 8 (Appendix). After correcting for mul-
tiple testing (corrected p ≤ 0.01), no probes remained signifi-
cantly associated with maternal depression severity in
pregnancy, prior to treatment.
Anxiety
Linear regression analysis (adjusted for birth weight, HM850
array chip position, sex, age, and allocation) revealed a total
of 3292 differentially methylated probes at a nominal signifi-
cance level (p < 0.01) between the groups of children from
the antenatally severely anxious women versus the group of
children from the antenatally mildly anxious women. Mean
DNA methylation values were not significantly different be-
tween the children born to severely anxious and the mildly
anxious women (mean Δβ= 0.0002 95% CI − 0.004 to 0.005,
p < 0.01). The top 100 differentially methylated probes ac-
cording to anxiety severity at baseline are presented in
Table 9 in Appendix. After correcting for multiple testing
(corrected p ≤ 0.01), no probes remained significantly associ-
ated with maternal anxiety severity in pregnancy, prior to
treatment.
Candidate gene-specific DNA methylation and baseline
depression/anxiety
Depression
Table 10 (Appendix) shows the results of the unpaired
Mann-Whitney-Wilcoxon tests, comparing mean DNA
methylation of 16 candidate genes between the groups of
children from the highly depressed and the mildly depressed
women. No genes were significantly differentially methylated
at a nominal significance level p < 0.01. Table 11 of the
Appendix shows the probes of the candidate genes that were
differentially methylated according to depression symptom
severity at a nominal significance level p < 0.01.
Anxiety
Table 12 (Appendix) shows the results of the unpaired
Mann-Whitney-Wilcoxon tests, comparing mean DNA
methylation of 16 candidate genes between the groups of
children from the highly anxious and the mildly anxious
women. No genes were significantly differentially methyl-
ated at a nominal significance level p < 0.01. A trend toward
higher DNA methylation was seen in the children from the
highly anxious mothers compared to the children of mildly
anxious mothers in theMEST gene. Table 11 of the Appen-
dix shows the probes of the candidate genes that were dif-
ferentially methylated according to anxiety symptom
severity at a nominal significance level p < 0.01.
The glucocorticoid receptor (NR3C1) gene and baseline
depression/anxiety
Depression
Mean DNA methylation of 34 promoter-associated NR3C1
probes (Table 13, Appendix) did not differ significantly be-
tween the groups of children from the highly depressed and
the mildly depressed women (mean Δβ = 0.006, 95% CI −
0.005 to 0.020).
Anxiety
Mean DNA methylation of 34 promoter-associated NR3C1
probes did not differ significantly between the groups of
children from the highly anxious and the mildly anxious
women (mean Δβ= 0.006, 95% CI − 0.005 to 0.020). Two
Table 2 Current characteristics of women and their children
participating in a DNA methylation study
Current demographics CBT (n = 12) TAU (n = 11)
Mean (SD) BDI score 16.1 (13.3) 14.9 (11.2)
Mean (SD) BAI score 11.3 (8.9) 10.9 (10.2)
Mean (SD) maternal age in years 40.0 (4.9) 40.6 (4.7)
Antidepressant use, n (%) 2 (16.7) 6 (54.4)
Mean (SD) child age in years 5.7 (1.2) 5.9 (1.0)
Mean (SD) child birth weight in grams 3547 (332) 3520 (590)
Gender (boys) (%) 58.3 63.6
Birth location (%)
- Australia 81.8 80.0
- Other 18.2 20.0
Marital status (%)
- Married 66.7 54.4
- De Facto 8.3 18.2
- Separated 8.3 18.2
- Single 16.7 9.1
Highest level of education (%)
- Did not finish school – –
- High School – 27.3
- Certificate Level/Apprenticeship 8.3 9.1
- Advanced Diploma 8.3 -
- Bachelor degree 25.0 9.1
- Graduate diploma/certificate 41.7 18.2
- Postgraduate Degree 16.7 36.4
Income (%)
- Up to $ 20,000 – 18.2
- $ 20,001–$ 40,000 8.3 18.2
- $ 40,001–$ 60,000 – 9.1
- $ 60,001–$ 80,000 8.3 9.1
- > $ 80,001 83.3 45.5
- Do not wish to divulge – –
Smokinga (%) 8.3 9.1
Alcoholb (%) 58.3 27.3
CBT cognitive behavioral therapy, TAU treatment as usual
a,bDefined as “currently consuming one or more alcoholic units per week or
smoking one or more cigarettes per week”
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Table 3 Top 100 differentially methylated probes according to intervention
CpG p Adjusted pa Gene Gene region Δβ
cg19908420 3.40E-06 0.999997557 0.049137862
cg15495292 4.01E-06 0.999997557 AIG1 Body 0.079710136
cg05155812 1.56E-05 0.999997557 SUN1 TSS1500 − 0.280713404
cg18818484 2.20E-05 0.999997557 PTCHD2 0.022078691
cg17622532 2.21E-05 0.999997557 0.024836631
cg14034519 2.27E-05 0.999997557 SNX1 Body 0.053471841
cg26436424 3.24E-05 0.999997557 NGEF Body 0.033261363
cg21494953 3.48E-05 0.999997557 C5orf23 TSS1500 0.036133838
cg19232929 3.58E-05 0.999997557 0.054387673
cg22342380 3.86E-05 0.999997557 0.03688025
cg13719771 5.98E-05 0.999997557 NDUFA9 Body 0.13765872
cg10356363 6.06E-05 0.999997557 CEBPB TSS1500 0.026639222
cg05205351 6.20E-05 0.999997557 NOP56 Body 0.05930508
cg14231326 6.23E-05 0.999997557 0.031289864
cg14358699 7.14E-05 0.999997557 0.047991502
cg06961812 8.01E-05 0.999997557 PRODH2 Body 0.058582642
cg16007230 8.39E-05 0.999997557 ABCC3 ExonBnd 0.036161879
cg25968469 8.53E-05 0.999997557 ARHGAP22 Body 0.056699144
cg23619591 8.80E-05 0.999997557 C19orf81 Body 0.057592082
cg09240747 0.000101189 0.999997557 0.067301777
cg18077049 0.000101567 0.999997557 GLRA3 Body 0.116790545
cg24435401 0.000110721 0.999997557 NPAS4 TSS1500 0.021387283
cg23274420 0.000110944 0.999997557 0.068615769
cg09223928 0.000111509 0.999997557 0.030359585
cg18666104 0.000115314 0.999997557 CORO1C Body 0.058415174
cg16273469 0.000115391 0.999997557 0.036049214
cg00541777 0.000120288 0.999997557 COLEC11 TSS1500 0.120518141
cg06646082 0.0001208 0.999997557 BTBD17 TSS1500 0.0430183
cg03711840 0.000127893 0.999997557 PLXNA1 Body 0.043191584
cg19465002 0.000130791 0.999997557 0.033852961
cg14687471 0.000134464 0.999997557 NBR2 Body 0.023128809
cg27243560 0.000134814 0.999997557 0.031689225
cg05510714 0.000135017 0.999997557 KYNU Body 0.153887531
cg12987887 0.000136898 0.999997557 UPB1 ExonBnd − 0.01972518
cg26836955 0.000138572 0.999997557 LONP1 Body 0.039104166
cg26330841 0.000138665 0.999997557 0.032962344
cg16720807 0.000142967 0.999997557 FAM176A 5′UTR 0.042119403
cg01440210 0.000143289 0.999997557 0.030341728
cg17068417 0.000144326 0.999997557 EEFSEC Body 0.030665165
cg15313810 0.000144443 0.999997557 ST6GALNAC4 Body 0.029787439
cg07545731 0.000147518 0.999997557 COL22A1 Body 0.04468122
cg14684297 0.000150469 0.999997557 ARHGAP33 5′UTR 0.032019831
cg10727673 0.000154265 0.999997557 TMEM22 TSS1500 0.089444195
cg04798314 0.000155738 0.999997557 SMYD3 Body 0.323390033
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Table 3 Top 100 differentially methylated probes according to intervention (Continued)
CpG p Adjusted pa Gene Gene region Δβ
cg11035122 0.000160944 0.999997557 MIR758 TSS1500 0.055539324
cg12360330 0.000168181 0.999997557 CENPJ Body 0.032193572
cg07469546 0.000172234 0.999997557 0.014405304
cg17785398 0.000172977 0.999997557 KCNJ6 Body 0.022656857
cg18291664 0.000173083 0.999997557 PRKAR1B Body 0.040654976
cg09319487 0.000181803 0.999997557 0.033053753
cg11510586 0.000186082 0.999997557 0.107251714
cg25441526 0.000188457 0.999997557 WDFY4 Body 0.025251026
cg19379103 0.000188787 0.999997557 SSBP3 Body 0.031870653
cg19769811 0.00019183 0.999997557 RASGRF2 TSS1500 0.046395706
cg26221509 0.000199233 0.999997557 SCUBE1 Body 0.039685931
cg14700416 0.000199451 0.999997557 SPOCK3 5′UTR 0.049430209
cg22746421 0.000200331 0.999997557 0.02669027
cg23553242 0.000200938 0.999997557 USP2 Body 0.043740484
cg06617093 0.000206244 0.999997557 0.032231234
cg08670534 0.000206305 0.999997557 COL2A1 Body 0.032117847
cg15791944 0.000212127 0.999997557 0.055152706
cg17562896 0.000216404 0.999997557 SV2C Body 0.037479302
cg02018176 0.000217297 0.999997557 KIAA1530 Body 0.047057842
cg11576176 0.000220243 0.999997557 GSX2 1stExon 0.03556139
cg09480336 0.0002295 0.999997557 POLD1 Body 0.03212232
cg21592262 0.000233681 0.999997557 0.06371313
cg12472342 0.000234117 0.999997557 − 0.069235248
cg18361948 0.00023564 0.999997557 0.029932491
cg00945089 0.000236572 0.999997557 GFRA1 Body 0.033266209
cg07442357 0.000238546 0.999997557 0.01892614
cg09193498 0.000239232 0.999997557 SEZ6 Body 0.042776024
cg02438610 0.000240811 0.999997557 SUN1 TSS1500 − 0.013139753
cg15037661 0.00024103 0.999997557 NR1D2 TSS1500 0.00946764
cg26264656 0.000243011 0.999997557 SKI Body 0.034797294
cg24367840 0.000243465 0.999997557 PSMD14 Body 0.057487682
cg05289897 0.000259274 0.999997557 0.012403078
cg16419764 0.000261486 0.999997557 CDYL Body 0.026043028
cg00248302 0.000266776 0.999997557 FCRL5 Body 0.028022889
cg24900542 0.000269678 0.999997557 0.085875055
cg15078841 0.000272298 0.999997557 0.022837528
cg12541879 0.000282436 0.999997557 PTPRN2 Body 0.056208383
cg01976641 0.000283246 0.999997557 0.05497368
cg17121322 0.000286514 0.999997557 0.025193249
cg17547875 0.000288231 0.999997557 0.01236688
cg18169610 0.000296554 0.999997557 CD81 Body 0.038708
cg04801704 0.000304651 0.999997557 TLL2 Body 0.025096532
cg23425290 0.000307508 0.999997557 ABCC1 Body 0.023343856
cg22680931 0.00030882 0.999997557 TMEM167B TSS1500 0.122894387
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probes, cg07515400 and cg22402730, showed a trend to-
ward higher DNA methylation in the children from severely
anxious mothers (Table 13, Appendix).
Discussion
In this follow-up of one of the first randomized controlled
trials on the effect of antenatal psychological depression
treatment (CBT) on children’s DNA methylation patterns,
we found no robust evidence of widespread methylation dif-
ferences between children of women in the control or inter-
vention group. However, at a pre-specified nominal
significance level of p < 0.01, 4780 differentially methylated
probes according to allocation pointed to an overall 2.7%
lower DNA methylation level of probes in children from the
intervention group. Applying a candidate approach,
non-significant trends toward lower DNA methylation in
the intervention group were seen in OXTR, MEST, MEG3,
H19, and CRHR2.We did not find a significant difference in
mean DNA methylation of 34 NR3C1 promoter-associated
probes between the intervention and control groups. Never-
theless, the majority of probes (68%) showed lower DNA
methylation in the intervention group compared to the con-
trol group, with cg26464411 as topmost differentially meth-
ylated probe, a CpG site that has been associated with
depression in earlier studies [25, 26]. Whether these trends
are persistent and clinically relevant remains to be deter-
mined in future studies with larger sample size and longer
follow-up.
Of the top five probes that were most differentially meth-
ylated between the intervention and the control group, three
corresponded to annotated genes: cg15495292 on the AIG1
gene, which is a gene involved in androgen regulation;
cg18818484 on the PTCHD2 gene, which is involved in
neuronal proliferation and differentiation; and cg05155812
on SUN1, a gene that potentially plays a role in neuronal mi-
gration and cerebellar development. These findings may be
Table 4 Top 10 differentially methylated genes according to allocation
CpG p Adjusted pa Gene Gene region Δß
cg19908420 3.40E-06 0.999998 0.049137862
cg15495292 4.01E-06 0.999998 AIG1 Body 0.079710136
cg05155812 1.56E-05 0.999998 SUN1 TSS1500 -?0.280713404
cg18818484 2.20E-05 0.999998 PTCHD2 Body 0.022078691
cg17622532 2.21E-05 0.999998 0.024836631
cg14034519 2.27E-05 0.999998 SNX1 Body 0.053471841
cg26436424 3.24E-05 0.999998 NGEF Body 0.033261363
cg21494953 3.48E-05 0.999998 C5orf23 TSS1500 0.036133838
cg19232929 3.58E-05 0.999998 0.054387673
cg22342380 3.86E-05 0.999998 0.03688025
?ß = mean ß(TAU) – mean ß(CBT)
CBT cognitive behavioral therapy, TAU treatment as usual, TSS transcription start site, UTR untranslated region
aCorrected for multiple testing [46]
Table 3 Top 100 differentially methylated probes according to intervention (Continued)
CpG p Adjusted pa Gene Gene region Δβ
cg01723825 0.000310423 0.999997557 URI1 TSS200 0.039217642
cg16261251 0.000311941 0.999997557 0.06722457
cg01400541 0.000314878 0.999997557 C10orf128 Body 0.042719378
cg26796807 0.000318004 0.999997557 0.04717045
cg10038145 0.000319876 0.999997557 POR Body 0.045738894
cg09078103 0.000320468 0.999997557 SNX9 Body 0.027261168
cg08880699 0.000322485 0.999997557 0.043133838
cg03116452 0.00032398 0.999997557 PLD3 5′UTR 0.034421382
cg03071994 0.000324145 0.999997557 NR4A1 Body 0.029626215
cg21485062 0.000324634 0.999997557 C7orf25 Body 0.024308813
cg11504793 0.000326763 0.999997557 NOL4L Body 0.025196146
cg04837576 0.00032871 0.999997557 ADRBK2 Body 0.030823149
Δβ = mean β (treatment as usual) − mean β (cognitive behavioral therapy)
TSS transcription start site, UTR untranslated region
aAdjusted for multiple testing [45]
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relevant as the desired effect of a prenatal intervention
would be to target genes that mediate the associations of
prenatal stress, depression or anxiety with adverse neurode-
velopmental disorders in children [27, 28]. Our results are
promising, but evidently replication in larger studies is
necessary.
Additionally, we revealed trends toward lower DNA
methylation in children from the intervention group com-
pared to the control group in 5 out of 16 candidate genes
that have previously been associated with prenatal exposure
to maternal stress, depression, or anxiety. These trends were
observed in OXTR, the gene coding for the Oxytocin recep-
tor; the MEST gene, a gene involved in metabolism; MEG3,
a long noncoding RNA; H19, an imprinted gene; and
CRHR1, a gene for corticotrophin releasing hormone recep-
tors. We did not find a significant difference in mean DNA
methylation between the intervention and control group on
the promoter region of the NR3C1 gene, coding for the
glucocorticoid receptor. Nevertheless, cg26464411 showed a
trend toward lower DNA methylation in the intervention
group. This CpG site has been positively correlated with
depressive symptoms or hypercortisolism in earlier studies
[25, 26]. Although our results were not significant, the
trends we have observed were in line with our expectations,
based on earlier findings from observational studies showing
increased methylation of NR3C1 in newborns and young
children of antenatally stressed, depressed, or anxious
women [20, 29], which was associated with increased stress
responses [21, 30].
The women in the current study were treated at a mean
of 18.6 weeks gestational age, and it may be possible that the
effect of treatment on offspring DNA methylation would
have been stronger if the women had been treated earlier in
their pregnancies. Increased attention is currently focused
on the period of early pregnancy, and even the preconcep-
tion period, as an important time window for adverse envir-
onmental factors inducing prenatal programming, which has
been shown in animal studies [18]. Further evidence in
humans is derived from studies examining prenatal famine,
in which the largest effect on offspring methylation was
found after prenatal exposure to undernutrition in early
pregnancy [31]. We did not test for an interaction between
allocation status and gestational age on mean methylation in
candidate genes because of the lack of significance in the ini-
tial analyses, but in larger future studies, exploring moder-
ation through gestational age would be highly informative to
identify treatment effects on DNA methylation during spe-
cific stages of pregnancy.
A limitation of the study was a lack of statistical power, as
we were only able to include approximately half (23/54 =
43%) of the original sample in this follow-up. Nevertheless,
associations between prenatal stress and methylation status
of NR3C1 have been reported in studies with a similar sam-
ple size [30, 32]. It was of interest that women who
participated in the current follow-up study had lower levels
of depression and anxiety at baseline compared to the par-
ticipants that were lost to follow-up (Table 1). Also, they
were observed to have higher incomes and were more
highly educated at baseline. However, attrition bias is not
likely to have occurred as this was the case in both groups
[33]. Despite no formal statistical tests being conducted [34],
it was evident that the difference in anxiety (BAI) scores be-
fore and after treatment between the intervention and con-
trol group was twice as high in the non-responders
compared to the responders (14.5 versus 7.5), indicating that
women with greater response to treatment were relatively
underrepresented in the current sample. Additionally, some
women in the control group also reported accessing psycho-
logical or medical treatment outside the trial [24]. This, and
the lower participation of those who responded better to
treatment, might have led to an underestimation of the ef-
fect of therapy on methylation profiles in the children in the
current study.
Although both groups were reasonably balanced in terms
of psychological and sociodemographic factors at the time
of follow-up, it is still possible that other, unmeasured fac-
tors are (partly) responsible for the trends observed in the
children’s epigenetic profiles according to allocation status.
Because of the small sample size of our study, we chose to
include only those variables that were likely to attribute
mostly to the variation in DNA methylation, such as child
gender, age, birth weight, and income. We did not include
educational attainment, although this also appeared to be
somewhat higher in the intervention group (although not
statistically significant, results not shown). In addition,
Fig. 2 Box plot indicates methylation values (%) for children that
were prenatally exposed to the intervention compared to control for
the CpG site on NR3C1 that was mostly associated with treatment
exposure: cg26464411. p (unadjusted for multiple testing) = 0.039.
CBT cognitive behavioral therapy, TAU treatment as usual
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maternal body composition in pregnancy, pregnancy com-
plications, and mode of delivery were not recorded in the
original study files, and hence, not included in the current
study. As these factors may act as mediators in the causal
path from improved mood in pregnancy to better child out-
comes, in future studies these variables should be included
as well. Nevertheless, we did have access to the children’s
birth weight, an important marker for general health of the
baby, which showed to be similar between both groups.
Also, we were unable to control for PC5 in the analyses, as
none of the variables included in the model was associated
with PC5. Nevertheless, the contribution fraction of PC5 to
the variation in DNA methylation was very marginal com-
pared to the contribution fraction of PC1, PC2, PC3, and
PC4, which were associated with known variables and there-
fore were controlled for in our analyses. Finally, we did not
adjust for cellular heterogeneity in our study. The most
widely applied method is the reference-based deconvolution
method originally described by Houseman et al., which per-
mits the estimation of the proportion of various cell types
within a sample based on existing reference data sets [35].
For blood, several studies have analyzed the methylation
profile of the specific cell- types present in whole blood,
which can serve as reference data. However, for saliva, this
has not been performed systematically, but studies that have
applied the Houseman deconvolution method on salivary
genome wide DNA methylation data (combining reference
methylomes from leucocyte subtypes and buccal epithelial
cells references methylomes) have shown that saliva is less
heterogenic compared to blood [36].
The impact of the postnatal environment on methylation
profiles in children also cannot be ignored. Exposure to
stressful life events from birth to adolescence has been asso-
ciated with higher NR3C1 methylation [37]. Although in
Fig. 3 Principal component analysis results of the variation in the HM850 methylation data. Principal component analysis revealed birth weight as the
major contributor to variation in the dataset with intervention status as the fifth largest contributor to variation in buccal cell DNA methylation profiles.
a Scree plot generated with M values for 770,668 probes on the HM850 array. Variance is shown on the y-axis, principal components are shown on the
x-axis. b Heatmap showing correlation coefficients, direction of correlations, and p values (bracketed) between principal components and various
clinical parameters. Shaded boxes indicate correlations between principal components and clinical parameters (set at p≤ 0.1)
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both intervention and control group, more women were
currently using antidepressant medication compared to
when they were pregnant at enrollment of the original study,
this was much more pronounced in the control group (rela-
tive increase of 43.3%) compared to the intervention group
(relative increase of 16.7%). These observations may be con-
sistent with a potential longer-term beneficial effect of treat-
ment in the women, which in turn, might have positively
affected child outcomes. Women from the intervention
group also reported higher incomes compared to baseline,
which was not the case in the control group, although in-
cluding income as additional covariate did not significantly
alter the results. To be able to isolate the effect of antenatal
CBT on offspring DNA methylation in utero, prior to any
postnatal confounding, evidence from trials that include
cord blood and/or placenta samples for DNA methylation
(and gene expression) are needed.
Finally, it has not yet been fully elucidated how maternal
depression affects child adversity. Nevertheless, epigenetic
modification of fetal genes in response to increased cortisol
exposure, either directly or via a decrease in placental inacti-
vation, has been widely accepted as a potential underlying
mechanism. Although our study findings could not robustly
support this hypothesis, the trends observed are in line with
earlier evidence. The existing evidence is nearly exclusively
based on findings from experiments in animals and observa-
tional human studies. The fact that the exploratory findings
from this novel experimental study in humans are in line
with the available evidence is therefore promising. It must
be noted that we mostly looked at statistically significant re-
sults at an uncorrected p-value level. The results of our
study should therefore be interpreted with caution. Al-
though the observed effect sizes were small, with mean dif-
ferences of 1–5% in methylation status, they are in line with
earlier evidence [20]. Because of the lack of studies with a
comparable study design, it is not yet possible to replicate
our findings in a similar trial; however, plans for a larger trial
are currently in progress.
Conclusion
We found preliminary evidence of a possible effect of cogni-
tive behavioral therapy during pregnancy on widespread
methylation and a non-significant trend towards lower
methylation of a specific CpG site previously linked to de-
pressive symptoms and child maltreatment in the interven-
tion group. However, none of the effects survived correction
for multiple testing. Larger studies are now warranted.
Methods
Study population
For the BBB study, women aged 18 years or over, and
less than 30 weeks pregnant were recruited through
screening programs at the Northern Hospital and Mercy
Hospital for Women, Melbourne, Australia, and via
Fig. 4 MDS plots, with samples colored according to CBT
(turquoise)/TAU (orange) status, showing the relatedness of samples
over the first four principal components of variation. CBT cognitive
behavioral therapy, TAU treatment as usual
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other health professionals and services in the public
(e.g., obstetricians, GPs, and PaNDA; a Perinatal Anxiety
and Depression helpline) and private sector (e.g., North-
park Private Hospital). The participating institutions
were reached through advertisement and encouraged to
refer women with suspected clinical depression. Women
scoring 13 points or higher on the Edinburgh Postnatal
Depression Scale (EPDS), the optimal score for detecting
depression during pregnancy [38], were referred to the
study for assessment by a psychologist if they consented.
They were included in the study if they met DSM-IV cri-
teria for a minor or major depressive disorder or an ad-
justment disorder with mixed depression and anxiety [39].
Severity of depression and anxiety symptoms was mea-
sured with the Beck Depression and Anxiety Inventories
[40, 41]. Women with comorbid axis I disorders or med-
ical conditions that were likely to interfere with study
participation, risk requiring crisis management, participa-
tion in other psychological programs, or significant diffi-
culty with English were excluded [24]. Women included
in the study (N = 54) were randomized to receive
pregnancy-specific CBT (N = 28) or TAU (N = 26). The
CBT program consisted of seven individual sessions and
one partner-session. TAU consisted of case-management
by a midwife or a general practitioner and referral to other
services of agencies as necessary. For ease of interpret-
ation, in the results sections of this paper, the group of
children of mothers from the CBT group will be referred
to as the “intervention” group, and the group of children
of mothers from the TAU group will be referred to as the
“control” group. For participation in the current study,
starting approximately 5 years after the BBB program had
ended, all participants were invited through a letter. If they
agreed to participate, an appointment at the Melbourne
Brain Institute was planned, and informed consent was
signed prior to or on the day of their visit to the clinic. If
women were not able to attend the clinic, they were in-
vited to send a buccal sample through the mail. The study
was approved by the Human Research Ethics Committees
of Austin Health, Melbourne, Australia.
Data collection
A questionnaire on current sociodemographic data and
current symptoms of depression and anxiety was sent to
each woman’s home address. Baseline demographics, includ-
ing symptoms of depression and anxiety as well as the
child’s birth weight, were taken from the BBB study files. At
the Melbourne Brain Centre, a cognitive assessment by
means of the Wechsler Preschool and Primary Intelligence
Scale (WWPSI-III) [42] was performed on the child, an
MRI scan of the child’s brain was conducted, of which re-
sults are described elsewhere, and a buccal cell sample from
the child was obtained by a researcher who was blinded to
the allocation status of the women.
Buccal cell samples
Buccal cells were collected using a dedicated swab (OraCol-
lect 100, DNA Genotek Inc., Ontario, Canada). Children
were instructed not to eat or drink 30 min prior to taking
the swab. Women who were not able to visit the Melbourne
Brain Centre were instructed how to apply the swab on their
child, and asked to send the sample via mail. The swabs
were stored at room temperature at the Parent-Infant Re-
search Institute and transported to the Murdoch Children’s
Research Institute (Melbourne, Australia) for DNA extrac-
tion within 2 weeks after collection.
DNA extraction and genome-wide methylation detection
DNA extraction of all samples was performed using the
NucleoBond CB20 DNA extraction kit. Purification of DNA
was assessed using Nanodrop Spectrophotometry. Bisulfite
conversion was performed using the EZ-96 DNA methyla-
tion kit (ZYMO Research Corporation) according to the
manufacturer’s instructions. DNA methylation profiling was
performed at the Australian Genome Research Facility, on
bisulfite converted DNA using the Illumina Infinium Methy-
lation EPIC BeadChip Array (HM850) (Illumina), which
measures CpG methylation at > 850,000 genomic sites.
Candidate gene approach
We extracted 729 probes spanning 16 a priori selected genes
for linear regression analysis. Candidate genes were those
that had previously been assessed in relation to prenatal ex-
posure to maternal stress, depression, and/or anxiety in earl-
ier studies [20]. Genes of interest were genes encoding
brain-derived neurotrophic factor (BDNF; 91 probes),
corticotrophin releasing hormone (CRH; 21 probes),
corticotrophin-releasing factor-binding protein (CRHBP; 25
probes), corticotrophin-releasing hormone receptors 1 and
2 (CRHR1; 41 probes, CRHR2; 40 probes), FK506 binding
protein (FKBP5; 49 probes), a long noncoding RNA (H19;
57 probes), hydroxysteroid 11-beta dehydrogenase 1 and 2
(HSD11B1; 25 probes, HSD11B2; 23 probes), insulin-like
growth factor (IGF2; 15 probes), maternally expressed 3
(MEG3; 87 probes), mesoderm-specific transcript homolog
protein (MEST; 63 probes), the glucocorticoid receptor
(NR3C1; 89 probes), the mineralocorticoid receptor (NR3C2;
50 probes), the oxytocin receptor (OXTR; 22 probes), and
the serotonin transporter (SLC6A4; 31 probes) [20].
Additionally, considering the especially strong evidence for
this gene, we separately analyzed the probes of the promoter
region of the glucocorticoid receptor gene (NR3C1
promoter-associated probes; 34 probes) for differential
methylation.
Statistical analysis
DNA methylation was defined as a continuous variable
varying from 0 (completely unmethylated) to 1 (completely
methylated). Methylation data were processed in R using
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the minfi package. Normalization of the data was per-
formed using the SWAN method [43]. Probes on X and
Y chromosomes, probes that were associated with SNPs
with a minor allele frequency > 1%, and cross-reactive
probes [44] were removed from the dataset. This re-
sulted in data for 770,668 probes available for subse-
quent analysis.
Sources of variation
Main contributors to the variation in the methylation
data were identified by principal component analysis
(PCA). We included the following variables in the ana-
lysis to assess associations with PC’s: participant ID, chip
ID, HM850 array chip position, allocation, sex, child age,
birth weight, maternal age, gestational age, current in-
come, baseline depression symptoms, baseline anxiety
symptoms, current depression symptoms, and current
anxiety symptoms. Results of the PCA showed that the
first five principal components contributed most to the
variation in the methylation data, and all variables asso-
ciated with any of these PC’s were added as covariate in
all analyses (Fig. 3a). The heatmap demonstrated that
allocation was associated with the third principal compo-
nent. Birth weight, child age, sex, and HM850 array chip
position were associated with the first four principal compo-
nents and they were included in the analyses as covariates.
None of the variables included in our model was signifi-
cantly associated with the fifth principal component, and
this PC was therefore not included in our model as covariate
(Fig. 3b). Unsupervised analysis by multidimensional scaling
was conducted in order to examine sources of variation
within the dataset. Beta values (methylation level) at all
HM850 probes for all samples were used to produce multi-
dimensional scaling (MDS) plots, with samples colored ac-
cording to intervention (turquoise)/control (orange) status,
showing the relatedness of samples over the first two princi-
pal components of variation (Fig. 4a). Coloring by
intervention/control revealed no distinct separation by allo-
cation. Additional MDS plots of samples over other princi-
pal components also failed to show a distinct separation
between the two groups (Figs. 4b c).
Differential methylation according to allocation
Linear regression analysis was used to identify
associations between the intervention status and
epigenome-wide DNA methylation. We took into ac-
count variation associated with the covariates birth
weight, HM850 array chip position, child sex and age,
to account for PC1, PC2, PC3, and PC4, as identified
by PCA. The Benjamini-Hochberg False-Discovery-Rate
method [45] was used to correct for multiple testing.
However, none of the analyses yielded significant differ-
entially methylated probes between the intervention
and control group after correcting for multiple testing.
In an explorative analysis, we extracted differentially
methylated probes between the intervention and con-
trol group at a nominal significance level set at p < 0.01,
prior to correcting for multiple testing. We assessed
differences in mean DNA methylation of all significant
probes between the intervention and control group
using an unpaired Mann-Whitney-Wilcoxon test. We
additionally compared mean beta differences of 16 can-
didate genes, and the promoter region of the NR3C1
gene between the intervention and control group using
an unpaired Mann-Whitney-Wilcoxon test.
Differential methylation according to baseline depression or
anxiety symptom score
As additional explorative analyses, two separate linear
regression models were also used to investigate associa-
tions between baseline depression (BDI–II score) and
baseline anxiety (BAI- score) with methylation profiles
in the children. For ease of interpretation, the sample
was divided into two groups in both analyses. The ra-
tionale behind this approach was to explore widespread
methylation variation between women with severe symp-
toms compared to those with mild symptoms using clin-
ically relevant cut-offs, rather than investigating the
direction of correlations between increasing depression
and anxiety scores on all probes separately. Baseline de-
pression was converted to a dichotomous variable using
clinically relevant Beck questionnaire cut-offs. Women
with BDI-II ≥ 29 were classified as “highly depressed” (n
= 13), whereas those with a score below 29 were classi-
fied as “mildly depressed” (n = 9) [46]. This procedure
was repeated for baseline anxiety (BAI-score). The
cut-off for clinically relevant anxiety is set at 16, and
therefore we classified women with BAI ≥ 16 as “highly
anxious” (n = 8), and women with BAI below 16 as
“mildly anxious” (n = 14) [47]. One woman had missing
data on baseline depression and anxiety and was ex-
cluded from the analysis. We took into account alloca-
tion status, birth weight, HM850 array chip position,
child sex, and age as covariates, as identified by PCA.
Differentially methylated probes at a nominal signifi-
cance level set at p < 0.01, prior to correction for mul-
tiple testing, were extracted. We compared differences
in mean DNA methylation in groups of children of
women with high baseline symptoms and low baseline
symptoms using an unpaired Mann-Whitney-Wilcoxon
test, both for depression and anxiety. We additionally
compared mean beta differences of 16 candidate genes,
and the promoter region of the NR3C1 gene between
groups of children of women with high baseline symptoms
and low baseline symptoms using an unpaired
Mann-Whitney-Wilcoxon test, both for depression and
anxiety.
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Appendix
Table 6 Probes in candidate gene analysis showing differential methylation according to intervention at uncorrected p < 0.01
CpG p Adjusted pa Gene Gene region Δβ
cg27338480 0.002299634 0.999997557 MEST 5′UTR 0.036568643
cg25579735 0.004343149 0.999997557 NR3C1 5′UTR − 0.028037036
cg01913022 0.0064351 0.999997557 CRHR2 TSS1500 0.068307524
cg03366382 0.006909299 0.999997557 INS-IGF2 TSS1500 0.044997291
cg03128167 0.009155461 0.999997557 IGF2 Body 0.017691809
Δβ = mean β (treatment as usual) − mean β (cognitive behavioral therapy)
TSS transcription start site, UTR untranslated region
aAdjusted for multiple testing [45]
Table 5 Differential mean methylation of candidate genes in buccal cell DNA of children after maternal antenatal CBT or TAU
Gene Δß 95%CI P
NR3C1 0.004 −0.004 to 0.011 0.32
NR3C1 Promoter 0.002 −0.010 to 0.011 0.65
SLC6A4 0.013 −0.007 to 0.035 0.09
OXTR 0.008 −4.7e-05 to 1.6e-02 0.04
NR3C2 0.002 −0.005 to 0.009 0.6
MEST 0.013 0.003 to 0.024 0.02
MEG3 0.012 0.00004 to 0.023 0.04
IFG2 0.005 −0.014 to 0.028 0.65
HSD11B1 0.004 −0.0123 to 0.019 0.61
HSD11B2 0.003 −0.003 to 0.010 0.29
H19 0.019 0.003 to 0.041 0.03
CRHR1 0.013 −0.0003 to 0.027 0.06
CRHR2 0.019 0.002 to 0.032 0.02
CRHRBP -0.003 −0.033 to 0.033 0.93
CRH 0.001 −0.014 to 0.015 0.98
BDNF 0.001 −0.005 to 0.008 0.38
FKBP5 0.006 −0.0003 to 0.0139 0.051
Δß = mean ß (TAU) - mean ß (CBT)
CBT cognitive behavioral therapy, TAU treatment as usual
Table 7 Differential methylation according to intervention (promoter-associated NR3C1 probes)
CpG p adjusted P1 Δβ
cg26464411 0.038765207 0.999997557 0.016954389
cg07515400 0.080810513 0.999997557 − 0.006695682
cg10847032 0.097881389 0.999997557 0.002994888
cg06952416 0.1418427 0.999997557 0.022027436
cg06968181 0.220252023 0.999997557 0.007404024
cg18019515 0.226633505 0.999997557 0.002112324
cg04111177 0.239037451 0.999997557 − 0.002860936
cg18068240 0.254658402 0.999997557 0.002064659
cg21209684 0.270282959 0.999997557 0.002460768
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Table 8 Top 100 differentially methylated probes according to baseline depression (BDI-II)
CpG p Adjusted pa Gene Gene region Δβ
cg01656717 5.43E-05 0.985858571 WWP2 Body 0.020713379
cg06022376 5.62E-05 0.985858571 CACTIN Body 0.031934062
cg01120173 5.91E-05 0.985858571 ZNF232 5′UTR − 0.032894902
cg24732447 8.42E-05 0.985858571 OSTM1 TSS1500 − 0.040891939
cg17402103 9.76E-05 0.985858571 0.044389084
cg10276665 0.000102293 0.985858571 PHF20 5′UTR − 0.053135525
cg23119960 0.000108933 0.985858571 TCF12 TSS1500 0.019411015
Table 7 Differential methylation according to intervention (promoter-associated NR3C1 probes) (Continued)
CpG p adjusted P1 Δβ
cg19135245 0.272388772 0.999997557 0.004258499
cg07733851 0.279542254 0.999997557 0.02357243
cg15910486 0.292918216 0.999997557 0.004537478
cg01967637 0.338536262 0.999997557 0.003919932
cg17860381 0.357836419 0.999997557 0.000876506
cg18849621 0.379245855 0.999997557 0.002552033
cg21702128 0.406504887 0.999997557 − 0.001070247
cg13764763 0.454791344 0.999997557 0.015622476
cg00629244 0.503885658 0.999997557 − 0.00246556
cg14939152 0.504120134 0.999997557 0.000577132
cg27122725 0.529860939 0.999997557 0.006029979
cg14558428 0.531421634 0.999997557 0.001417758
cg08818984 0.551707805 0.999997557 − 0.030134797
cg24026230 0.564518425 0.999997557 0.002507375
cg03906910 0.630630252 0.999997557 − 0.02119966
cg13648501 0.652981749 0.999997557 0.001717513
cg16335926 0.740313284 0.999997557 − 0.001532178
cg26720913 0.743323678 0.999997557 − 0.017368038
cg17342132 0.818325933 0.999997557 0.011875955
cg18718518 0.88056981 0.999997557 0.004555236
cg22402730 0.908119964 0.999997557 − 0.000126521
cg15645634 0.908177372 0.999997557 − 0.001196809
cg23776787 0.933952752 0.999997557 − 0.00580295
cg11152298 0.951420262 0.999997557 0.000520728
cg18998365 0.961116448 0.999997557 0.001743816
Δβ = mean β (treatment as usual) − mean β (cognitive behavioral therapy)
TSS transcription start site, UTR untranslated region
aAdjusted for multiple testing [45]
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Table 8 Top 100 differentially methylated probes according to baseline depression (BDI-II) (Continued)
CpG p Adjusted pa Gene Gene region Δβ
cg07639472 0.000110211 0.985858571 GABARAP TSS200 0.009595275
cg14522236 0.000112046 0.985858571 − 0.049713856
cg16561657 0.000150143 0.985858571 − 0.055819652
cg21014120 0.00015174 0.985858571 ICA1L TSS200 − 0.006901363
cg02965870 0.000158156 0.985858571 NEDD4 1stExon − 0.005222348
cg19817882 0.000171789 0.985858571 LEFTY1 Body 0.034762224
cg02644616 0.000173319 0.985858571 − 0.00792669
cg00369151 0.000179443 0.985858571 PIP4K2A Body − 0.036713932
cg24954665 0.000194603 0.985858571 − 0.018476691
cg08217452 0.000200085 0.985858571 0.062010845
cg22796353 0.000209579 0.985858571 − 0.06798597
cg05636467 0.000213261 0.985858571 EBF3 Body 0.058972943
cg01870580 0.000213772 0.985858571 SGCD Body − 0.033578993
cg04167481 0.000227738 0.985858571 LRRC6 Body − 0.02281918
cg07010552 0.000233 0.985858571 CHRNB1 Body 0.03251269
cg09877950 0.000238965 0.985858571 SLC4A10 Body − 0.050949676
cg08548444 0.000241925 0.985858571 0.058594659
cg22870344 0.000242958 0.985858571 ATP5B TSS200 0.040824173
cg16692066 0.000251174 0.985858571 FNDC7 Body − 0.027886693
cg03781315 0.00025551 0.985858571 AHCY Body − 0.020798236
cg18303019 0.000261834 0.985858571 TXNRD1 TSS1500 − 0.03100706
cg07381391 0.000267381 0.985858571 0.203102371
cg17115402 0.000269335 0.985858571 CDR2L Body − 0.020519014
cg23788051 0.000272662 0.985858571 0.034154924
cg15234197 0.000277725 0.985858571 0.09308691
cg22521539 0.000282937 0.985858571 0.049648454
cg25157095 0.000284638 0.985858571 RIPK4 Body 0.029861946
cg25464078 0.000290016 0.985858571 PPTC7 Body 0.041450584
cg24667213 0.000295285 0.985858571 0.021353983
cg03716908 0.00029717 0.985858571 0.036164552
cg11747082 0.000319919 0.985858571 GPR33 TSS1500 − 0.043309753
cg08446512 0.000321548 0.985858571 MIR548Q Body − 0.057652312
cg10239816 0.000321981 0.985858571 GOT1 TSS200 0.010999285
cg24632014 0.000329696 0.985858571 LOC100189589 Body 0.033737209
cg14255237 0.000331265 0.985858571 SARDH Body 0.068885565
cg01874640 0.000341932 0.985858571 HGD ExonBnd − 0.027385445
cg12308055 0.000342843 0.985858571 VAC14 Body 0.025670901
cg13747435 0.000353254 0.985858571 AK1 Body 0.02153699
cg26287679 0.000353404 0.985858571 MYBL1 Body − 0.036514738
cg27305222 0.000359452 0.985858571 − 0.040634637
cg09694986 0.000364186 0.985858571 SNTB1 Body − 0.041411009
cg04928577 0.000370129 0.985858571 − 0.069549039
cg02059927 0.000376777 0.985858571 0.045567447
cg19553615 0.000379462 0.985858571 CRTC3 Body 0.021785594
Bleker et al. Clinical Epigenetics           (2019) 11:18 Page 16 of 24
Table 8 Top 100 differentially methylated probes according to baseline depression (BDI-II) (Continued)
CpG p Adjusted pa Gene Gene region Δβ
cg06214427 0.000382521 0.985858571 MYO1A Body − 0.027829513
cg14609960 0.000388595 0.985858571 PITRM1 Body − 0.03071115
cg07814876 0.000392304 0.985858571 GGPS1 5′UTR 0.02176791
cg03656020 0.000394532 0.985858571 VGF 3′UTR 0.02323939
cg16977720 0.000414373 0.985858571 TRABD2A Body − 0.015144172
cg11173076 0.00041489 0.985858571 ART1 TSS200 0.051579054
cg11407226 0.000427414 0.985858571 0.052957159
cg24676514 0.000428063 0.985858571 0.007114356
cg24353217 0.000430568 0.985858571 MYL2 Body 0.048161701
cg13022689 0.000438434 0.985858571 − 0.014053374
cg08013270 0.000452709 0.985858571 EMX1 Body 0.009802214
cg10486455 0.000457554 0.985858571 WDR46 Body − 0.071572335
cg08824610 0.000457605 0.985858571 SCN3B Body 0.032374425
cg23934072 0.00046317 0.985858571 KIF21B 3′UTR 0.072005944
cg08882432 0.000492053 0.985858571 CCDC171 Body − 0.06825542
cg19075081 0.000509177 0.985858571 MTSS1L Body 0.034977378
cg14940449 0.000513204 0.985858571 HGS TSS200 − 0.004493762
cg27644292 0.000535008 0.985858571 SNRPN 5′UTR − 0.043063624
cg13277044 0.000537047 0.985858571 − 0.028669058
cg10313065 0.000547596 0.985858571 0.027390264
cg27483342 0.000549745 0.985858571 − 0.035483152
cg00167525 0.00054993 0.985858571 − 0.044404069
cg02624701 0.000556261 0.985858571 SLC17A7 Body − 0.023735747
cg24488506 0.000559886 0.985858571 FOSL1 1stExon − 0.005249818
cg10894284 0.000567688 0.985858571 SPATS2 Body − 0.05283773
cg00045787 0.0005679 0.985858571 SNTB2 Body 0.021702408
cg22379574 0.000572536 0.985858571 TPT1 TSS200 0.002542434
cg09381162 0.000579437 0.985858571 ANXA13 Body − 0.038107869
cg10562399 0.000581216 0.985858571 SNRPG Body 0.049683592
cg17422878 0.000584164 0.985858571 − 0.01955572
cg16460816 0.000592284 0.985858571 IFT140 Body 0.016906513
cg22647874 0.000594316 0.985858571 FAM192A 5′UTR − 0.01781755
cg04157647 0.000594803 0.985858571 CD27-AS1 Body − 0.068075731
cg14436051 0.000595366 0.985858571 PRR26 Body − 0.018081196
cg11629443 0.000598589 0.985858571 TRIM27 1stExon 0.005616034
cg03163982 0.00059979 0.985858571 − 0.008328044
cg11475558 0.000600783 0.985858571 TNS1 Body 0.028042851
cg18014277 0.000608293 0.985858571 APBB1IP 3′UTR − 0.016579214
cg02597373 0.000619621 0.985858571 UNC13D Body 0.05993223
cg23123838 0.000622213 0.985858571 MTA1 TSS200 0.023497892
cg03278573 0.000627109 0.985858571 DAP Body − 0.064990789
cg15674937 0.000643134 0.985858571 0.073468304
cg01126532 0.000643521 0.985858571 − 0.081499283
cg04736676 0.000662804 0.985858571 MCM3AP TSS1500 0.012334518
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Table 8 Top 100 differentially methylated probes according to baseline depression (BDI-II) (Continued)
CpG p Adjusted pa Gene Gene region Δβ
cg11240430 0.000664374 0.985858571 ANKRD16 5′UTR 0.017463959
cg00154646 0.000664385 0.985858571 − 0.022644413
cg06434997 0.000669569 0.985858571 FBXO5 5′UTR 0.023162548
cg02030350 0.00067758 0.985858571 Body − 0.030538262
cg13357903 0.000693814 0.985858571 MIA3 TSS1500 0.012988536
Δβ = mean β (severely depressed) − mean β (mildly depressed)
TSS transcription start site, UTR untranslated region
aAdjusted for multiple testing [46]
Table 9 Top 100 differentially methylated probes according to baseline anxiety (BAI)
CpG p Adjusted pa Gene Gene region Δβ
cg06513375 1.01E-06 0.77590274 ZNF251 Body − 0.106421132
cg19573881 5.11E-06 0.998778059 0.083994741
cg00117018 1.40E-05 0.998778059 ZNF251 Body − 0.13038673
cg11602361 3.18E-05 0.998778059 FYN 5′UTR − 0.045924181
cg21641920 3.80E-05 0.998778059 RBM33 Body − 0.056092107
cg13511253 4.12E-05 0.998778059 MAPK4 5′UTR − 0.06921116
cg11674381 4.68E-05 0.998778059 − 0.030888002
cg00115113 5.01E-05 0.998778059 LINC00483 Body 0.027732238
cg21918548 5.84E-05 0.998778059 ZNF251 Body − 0.100935223
cg01519784 5.87E-05 0.998778059 − 0.025857817
cg07081372 6.58E-05 0.998778059 TMX1 Body 0.020743268
cg26293081 7.19E-05 0.998778059 TNS3 Body 0.039738087
cg06626791 7.25E-05 0.998778059 CCNE2 5′UTR 0.012276869
cg04788249 7.26E-05 0.998778059 ATG7 5′UTR 0.003609404
cg08049441 7.76E-05 0.998778059 RPL32P3 Body − 0.024015531
cg10731606 8.45E-05 0.998778059 AGBL3 TSS200 0.031982023
cg02335517 0.000117192 0.998778059 IL6 Body − 0.013920705
cg12379948 0.00011944 0.998778059 WNT3 TSS1500 0.007283815
cg13242754 0.000127218 0.998778059 C14orf101 Body − 0.015166989
cg06245967 0.000130491 0.998778059 BANP 5′UTR − 0.029761211
cg21643916 0.000138817 0.998778059 PRKAR1B Body − 0.013338272
cg22500132 0.000147833 0.998778059 MUC1 TSS200 0.00823408
cg24555816 0.000150316 0.998778059 0.058918432
cg02893361 0.000160529 0.998778059 PIAS1 Body − 0.030954487
cg12906188 0.000164316 0.998778059 RGS4 Body 0.008487123
cg05524951 0.000170319 0.998778059 − 0.012679223
cg14122980 0.000170584 0.998778059 PTPRD 5′UTR − 0.023320139
cg13449967 0.000178787 0.998778059 ATG2A Body 0.029533776
cg17231980 0.000185655 0.998778059 − 0.013659095
cg04657000 0.000189668 0.998778059 FYN 5′UTR − 0.012205559
cg18612255 0.000205249 0.998778059 0.012801625
cg22063222 0.000229138 0.998778059 − 0.010538791
cg23760165 0.000231842 0.998778059 FADS2 TSS1500 0.00669263
cg24531534 0.000237063 0.998778059 LOXL2 Body 0.102423109
cg15745507 0.000240352 0.998778059 0.039058624
cg05731717 0.000243608 0.998778059 − 0.038853941
cg16888838 0.000245704 0.998778059 KIAA1549 3′UTR − 0.021553937
cg17190403 0.000249731 0.998778059 C6orf211 Body 0.029783554
cg18298090 0.000274478 0.998778059 ETV2 TSS1500 − 0.035320986
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Table 9 Top 100 differentially methylated probes according to baseline anxiety (BAI) (Continued)
CpG p Adjusted pa Gene Gene region Δβ
cg11341317 0.000285303 0.998778059 − 0.032941327
cg15264808 0.000285946 0.998778059 CENPN 5′UTR 0.012161477
cg21025551 0.000290064 0.998778059 ADRBK2 TSS200 0.008238703
cg15872329 0.000304128 0.998778059 BLOC1S2 Body 0.010747948
cg26594377 0.000311806 0.998778059 EFCAB11 5′UTR 0.007818559
cg27191554 0.000311819 0.998778059 NOTCH3 Body 0.016376385
cg25899954 0.000314492 0.998778059 − 0.015053877
cg09602803 0.000326585 0.998778059 0.052616473
cg23462514 0.000333695 0.998778059 RNF212 TSS200 − 0.085842379
cg18193440 0.000336288 0.998778059 TAF1L 1stExon 0.071586528
cg09398891 0.000343573 0.998778059 − 0.017821675
cg08949296 0.000351898 0.998778059 JPH1 1stExon 0.008914397
cg21943599 0.000355323 0.998778059 C1orf125 TSS1500 − 0.012630326
cg04322378 0.000356074 0.998778059 LINC01258 TSS200 0.036276539
cg13921204 0.000358982 0.998778059 SEC61A2 TSS200 0.004130793
cg07346187 0.000360053 0.998778059 ZC3H12D Body 0.008900888
cg11832804 0.000361177 0.998778059 TERT Body − 0.006660909
cg04899629 0.00036328 0.998778059 LOR2C3 TSS1500 − 0.067707778
cg01985858 0.000364399 0.998778059 OBFC2B TSS1500 0.012234912
cg03851648 0.000366413 0.998778059 PHC2 Body − 0.103038845
cg11102724 0.000382353 0.998778059 0.200746665
cg18570658 0.000387535 0.998778059 COL4A2 Body − 0.06295432
cg24942330 0.000389195 0.998778059 ASAH1 TSS1500 0.005198328
cg07571142 0.00039639 0.998778059 C10orf99 3′UTR − 0.022383608
cg14405643 0.000402335 0.998778059 IER5L 3′UTR 0.026828829
cg13147522 0.000402551 0.998778059 SAPS3 TSS200 0.011988911
cg15417944 0.000405638 0.998778059 RBM44 5′UTR − 0.03261725
cg00616952 0.000409576 0.998778059 SIPA1L3 Body − 0.019003771
cg23166923 0.000410512 0.998778059 PMPCA 1stExon 0.008004775
cg13297582 0.000411378 0.998778059 LDLRAD4 5′UTR − 0.092481987
cg00962271 0.000413861 0.998778059 − 0.042309368
cg11640106 0.000416865 0.998778059 LOC101929194 Body − 0.016168103
cg06981781 0.000418137 0.998778059 EGF Body − 0.011108508
cg24146773 0.000418853 0.998778059 SH3BGR 1stExon − 0.083744695
cg23579746 0.000438092 0.998778059 FCRLB TSS1500 − 0.026251069
cg09819772 0.000438692 0.998778059 − 0.019080858
cg06630983 0.000440009 0.998778059 PPM1F Body − 0.013620731
cg09207053 0.000444686 0.998778059 PCDHGA11 TSS200 0.021510517
cg11833983 0.000447858 0.998778059 KANSL2 Body − 0.020712784
cg05675803 0.000455891 0.998778059 C6orf52 Body 0.006716337
cg03265692 0.000455941 0.998778059 ATAD1 TSS1500 0.010548663
cg11463903 0.000458655 0.998778059 ING5 TSS1500 0.015381351
cg03211481 0.00046527 0.998778059 DNAJC1 Body − 0.022278955
cg17714799 0.000472182 0.998778059 CASP6 TSS1500 0.018907097
cg20034712 0.000482406 0.998778059 ZNF836 TSS1500 − 0.060359087
cg11554391 0.000485943 0.998778059 AHRR Body 0.014764295
cg06166863 0.000490293 0.998778059 PNN TSS200 0.007284371
cg26321013 0.000491445 0.998778059 WIPF2 1stExon 0.018566869
cg16261619 0.000495054 0.998778059 ZPBP TSS200 − 0.049720147
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Table 9 Top 100 differentially methylated probes according to baseline anxiety (BAI) (Continued)
CpG p Adjusted pa Gene Gene region Δβ
cg06871884 0.000495095 0.998778059 LINC00963 Body 0.008107368
cg16333300 0.000496236 0.998778059 TECTA Body − 0.023279226
cg21848211 0.000497682 0.998778059 − 0.019228316
cg16287252 0.00050262 0.998778059 GLT1D1 Body − 0.059937553
cg15568778 0.000504593 0.998778059 − 0.009418856
cg15247039 0.000514355 0.998778059 − 0.026521804
cg04800443 0.000518233 0.998778059 0.034208928
cg12937337 0.000519654 0.998778059 PTEN 5′UTR − 0.020668502
cg05308125 0.000534128 0.998778059 − 0.017025401
cg13267264 0.000538758 0.998778059 PRDM14 TSS200 0.023761421
cg06610641 0.000538794 0.998778059 ZNF527 TSS1500 0.019166156
cg16642284 0.00053992 0.998778059 FOXI2 TSS200 0.019871733
Δβ = mean β (severely anxious) − mean β (mildly anxious)
TSS transcription start site, UTR untranslated region
aAdjusted for multiple testing [46]
Table 10 Differential methylation of candidate genes according to baseline depression (BDI-II)
Gene Δβ 95% CI p
NR3C1 0.002 − 0.006 to 0.011 0.647
NR3C1 Promoter 0.006 − 0.005 to 0.020 0.2093
SLC6A4 0.004 − 0.022 to 0.028 0.647
OXTR 0.003 − 0.009 to 0.010 0.5123
NR3C2 − 0.002 − 0.012 to 0.007 0.647
MEST 0.009 − 0.002 to 0.018 0.1264
MEG3 0.007 − 0.008 to 0.0120 0.2921
IFG2 − 0.006 − 0.035 to 0.018 0.6005
HSD11B1 − 0.002 − 0.022 to 0.017 0.7938
HSD11B2 0.004 − 0.005 to 0.009 0.2093
H19 0.016 − 0.011 to 0.039 0.2624
CRHR1 0.008 − 0.016 to 0.0221 0.3575
CRHR2 0.005 − 0.014 to 0.0246 0.647
CRHRBP 0.011 − 0.0262 to 0.0372 0.5556
CRH − 0.006 − 0.017 to 0.009 0.3237
BDNF 0.003 − 0.001 to 0.010 0.1641
FKBP5 0.003 − 0.023 to 0.031 0.7414
Δβ = mean β (severely depressed) − mean β (mildly depressed)
Table 11 Probes in candidate gene analysis showing differential methylation according to baseline depression (BDI-II) at
uncorrected p < 0.01
CpG p Adjusted pa Gene Gene region Δβ
cg17578833 0.002812934 0.985858571 CRH TSS1500 − 0.055448723
cg04137760 0.00427371 0.985858571 FKBP5 5′UTR − 0.028541521
cg08077673 0.007257559 0.985858571 MEST 5′UTR 0.008859633
cg07583420 0.00759847 0.985858571 IGF2 Body 0.00580552
cg13167664 0.009158888 0.985858571 IGF2 Body 0.003859675
Δβ = mean β (severely depressed) − mean β (mildly depressed)
TSS transcription start site, UTR untranslated region
aAdjusted for multiple testing [45]
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Table 12 Differential methylation of candidate genes according to baseline anxiety (BAI)
Gene Δβ 95% CI p
NR3C1 − 0.006 − 0.013 to 0.004 0.2382
NR3C1 Promoter 0.008 − 0.001 to 0.019 0.0817
SLC6A4 0.005 − 0.022 to 0.028 0.5699
OXTR − 0.004 − 0.015 to 0.005 0.3301
NR3C2 0.004 − 0.007 to 0.011 0.4411
MEST 0.013 0.001 to 0.023 0.01965
MEG3 0.012 − 0.0005 to 0.025 0.06983
IFG2 − 0.004 − 0.028 to 0.026 0.7135
HSD11B1 0.009 − 0.008 to 0.027 0.2667
HSD11B2 0.005 − 0.003 to 0.012 0.11
H19 0.014 − 0.009 to 0.039 0.2382
CRHR1 0.003 − 0.015 to 0.021 0.6163
CRHR2 0.001 − 0.018 to 0.024 0.9734
CRHRBP 0.016 − 0.021 to 0.045 0.4411
CRH − 0.007 − 0.019 to 0.006 0.402
BDNF 0.007 − 0.0007 to 0.011 0.0817
FKBP5 0.005 − 0.003 to 0.014 0.145
Δβ = mean β (severely anxious) − mean β (mildly anxious)
Table 13 Differential methylation according to baseline anxiety (BAI) (promoter-associated NR3C1 probes)
CpG p Adjusted pa Gene region Δß
cg07515400 0.019543236 0.998778059 TSS1500 0.008757408
cg22402730 0.034941814 0.998778059 TSS1500 0.007846464
cg18068240 0.074595651 0.998778059 5'UTR 0.003513867
cg00629244 0.075603387 0.998778059 TSS200 0.005153991
cg21209684 0.095644074 0.998778059 5'UTR 0.005819462
cg17860381 0.172486506 0.998778059 5'UTR −0.007857672
cg18849621 0.181055644 0.998778059 TSS1500 0.007722928
cg26720913 0.22868997 0.998778059 1stExon 0.071542284
cg16335926 0.238092713 0.998778059 TSS1500 0.002021547
cg24026230 0.24577813 0.998778059 5'UTR 0.005938353
cg18019515 0.245786808 0.998778059 TSS200 0.001549976
cg23776787 0.295148027 0.998778059 1stExon 0.055157644
cg11152298 0.296050346 0.998778059 TSS200 0.003074345
cg17342132 0.318902496 0.998778059 Body −0.021285299
cg27122725 0.347102162 0.998778059 5'UTR 0.035263092
cg10847032 0.355174482 0.998778059 TSS1500 −0.000186142
cg21702128 0.358888726 0.998778059 TSS1500 0.003153478
cg26464411 0.373131972 0.998778059 TSS1500 0.008722328
cg18998365 0.436272234 0.998778059 5'UTR 0.005641782
cg06968181 0.486353571 0.998778059 TSS1500 0.004702526
cg03906910 0.524841281 0.998778059 1stExon 0.051231481
cg14939152 0.572528468 0.998778059 5'UTR −0.003292981
cg04111177 0.59537643 0.998778059 5'UTR 0.002463121
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Table 13 Differential methylation according to baseline anxiety (BAI) (promoter-associated NR3C1 probes) (Continued)
CpG p Adjusted pa Gene region Δß
cg06952416 0.665139695 0.998778059 5'UTR 0.036482196
cg08818984 0.673915225 0.998778059 1stExon 0.043838345
cg13648501 0.723256995 0.998778059 5'UTR 0.008987005
cg19135245 0.779311238 0.998778059 TSS1500 0.001611098
cg07733851 0.816930585 0.998778059 5'UTR 0.029161123
cg15645634 0.864608392 0.998778059 5'UTR −0.002973062
cg01967637 0.911624523 0.999388148 5'UTR −0.004461401
cg14558428 0.913633924 0.999388148 5'UTR 0.000461939
cg18718518 0.937744615 0.999400864 TSS1500 0.023943315
cg13764763 0.939306554 0.999410992 TSS1500 0.012472219
cg15910486 0.975291537 0.999632341 5'UTR −0.003768688
?ß = mean ß (severely anxious) - mean ß (mildly anxious)
TSS transcription start site, UTR untranslated region
aAdjusted for multiple testing [45]
Table 14 Probes in candidate gene analysis showing differential methylation according to baseline anxiety (BAI) at
uncorrected p?<?0.01
CpG p Adjusted pa Gene Gene region Δß
cg26880525 0.00670039 0.998778059 HSD11B1 5'UTR −0.07833178
cg07704699 0.007191379 0.998778059 BDNF Body 0.026796044
cg13670288 0.007464434 0.998778059 IGF2 Body −0.003490477
cg23273257 0.009092701 0.998778059 NR3C1 3'UTR −0.014724328
?ß = mean ß (severely anxious) - mean ß (mildly anxious)
TSS transcription start site, UTR untranslated region
aAdjusted for multiple testing [45]
Table 15 Differential methylation according to baseline depression (BDI-II) (promoter-associated NR3C1 probes)
CpG p Adjusted pa Gene region Δβ
cg22402730 0.09232524 0.985858571 TSS1500 0.007914958
cg07515400 0.14983598 0.985858571 TSS1500 0.00381786
cg18849621 0.155838866 0.985858571 TSS1500 0.011301146
cg27122725 0.191928791 0.985858571 5′UTR 0.04731291
cg19135245 0.244476459 0.985858571 TSS1500 0.005449225
cg01967637 0.254982491 0.985858571 5'UTR − 0.002502373
cg21702128 0.310632555 0.985858571 TSS1500 0.003068137
cg06968181 0.341577022 0.985858571 TSS1500 0.015388067
cg26464411 0.354871977 0.985858571 TSS1500 0.018949214
cg14558428 0.355258299 0.985858571 5′UTR 0.000239683
cg00629244 0.377208819 0.985858571 TSS200 − 0.003861647
cg08818984 0.399423704 0.985858571 1stExon 0.000741573
cg23776787 0.447963073 0.985858571 1stExon 0.016867225
cg13648501 0.469320108 0.985858571 5′UTR 0.016976965
cg03906910 0.497810362 0.985858571 1stExon 0.010141716
cg18068240 0.512386308 0.985858571 5′UTR 0.00411793
cg21209684 0.572146062 0.985858571 5'UTR 0.00264155
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